The classification of colorectal cancer (CRC) by microsatellite instability (MSI) status is important for effective clinical management. In fact, microsatellite instability-high (MSI-H) cancer has distinctive clinicopathological and molecular features. However, microsatellite instability-low (MSI-L) cancer is not clearly defined. The objective of this study was to further clarify the characteristics of MSI-L CRC. A consecutive series of 940 primary CRCs were subdivided into three groups according to the level of MSI and analyzed the clinicopathological features and genetic changes in the KRAS, BRAF and p53 mutation and the loss of heterozygosity (LOH) of adenomatous polyposis coli (APC) gene and methylation status of the O 6 -methylguanine-DNA methyltransferase (MGMT) and MLH1 promoter. Of the 940 CRCs, 5.9% were MSI-H, 7.1% were MSI-L and 87% were microsatellite stable (MSS). KRAS and BRAF mutations were detected in 39.4 and 4.6% of the CRCs, respectively. The frequency of KRAS mutations in MSI-H, MSI-L and MSS cancer was 30, 48 and 39%, respectively. The proportion of KRAS mutations in MSI-L cancer increased from 16 to 63% accompanying the progression from Dukes' A to Dukes' B. While the LOH of D5S346, which is located near the APC gene, and p53 mutation was observed in 75 and 67% of MSI-L CRC at Dukes' A, respectively. These results indicated that the LOH of APC and p53 mutation has already occurred by the Dukes' A lake 'suppressor pathway' but not the KRAS mutation in MSI-L CRCs. The genes involving MSI-L carcinogenesis are similar to MSS but the timing and frequency of the KRAS mutation is different.
Introduction
There are two types of genomic instability, microsatellite instability (MSI or MIN) or chromosomal instability associated with the carcinogenesis process of colorectal cancer (CRC) (1) . The great majority of CRCs develop through the chromosomal instability pathway (also called the 'suppressor pathway'), which arise from adenomas and is initiated by the inactivated adenomatous polyposis coli (APC) gene and followed by the well-established genetic steps involved in the adenoma-carcinoma sequence (2, 3) . While another type of genomic instability, MSI caused by a failure of the DNA mismatch repair (MMR) system, is observed in $10% of all CRCs (4-7). DNA MMR deficiency leads mutations in the target genes that are implicated in tumor progression such as TGFbetaR2 (8) , IGF2R (9), CDX2 (10) and BAX (11) and it is known as the 'mutator pathway'. MSI can be subdivided into three groups, microsatellite instability-high (MSI-H), microsatellite instability-low (MSI-L) and microsatellite stable (MSS), according to the degree of instability. The recommended method to distinguish these subgroups is to analyze paired tumor and normal tissue DNAs using a panel of five microsatellite markers known as the Bethesda panel (12) .
The MSI-H CRCs phenotype is more likely to occur at a proximal site, to occur in women, to be associated with a favorable prognosis (5, 7, (13) (14) (15) and severe inflammatory cell infiltration into the tumor tissue (16, 17) . A large percent of MSI-H CRC is sporadic and demonstrates somatic promoter methylation of the hMLH1 gene (18, 19) , whereas a germ line mutation of the MMR genes, such as hMSH2, hMLH1, hMSH6 and hPMS2, is found in the majority of MSI-H CRC without hMLH1 promoter methylation and is known as Lynch syndrome/hereditary non-polyposis colorectal cancer (20) (21) (22) (23) . Recent morphological and molecular studies have proposed the existence of a serrated pathway, thus suggesting that serrated polyps may serve as a precursor of the MSI-positive cancers (24) (25) (26) .
On the other hand, most studies have found no obvious clinicopathological or molecular differences between MSI-L and MSS cancers (27) . The DNA MMR genes hMLH1 and hMLH2 do not appear to be implicated in the MSI-L subset (28) . Some studies have reported that MSI-L is associated with cancers from individuals with germ line mutations of hMLH6 (29) , but genetic alteration of this gene is infrequent in MSI-L CRC patients. Furthermore, some researchers deny the presence of MSI-L cancers because most non-MSI-H cancers exhibit MSI-L when large numbers of microsatellite loci are tested (27, 30) .
Meanwhile, there is evidence indicating that the MSI-L phenotype could reflect a distinct pathway of tumor development with a different clinical behavior and different genetic and epigenetic changes. For example, a high frequency of a KRAS mutation (31, 32) that is associated with loss of expression of the O 6 -methylguanine-DNA methyltransferase (MGMT) gene by methylation of its promoter region (33) , lower frequency of 5qLOH (31), a high frequency of APC mutation (34) and reduced expression of Bcl-2 protein (35) are global molecular phenotypes by which MSI-L cancers are distinguished from non-MSI-L cancers.
Therefore, MSI-L CRC is still controversial. This study investigated the genetic changes and clinicopathological features of MSI-L CRCs using a series of 940 CRCs.
Materials and methods
Patients and tissue samples A consecutive series of 940 primary CRCs excised surgically at Saitama Cancer Center from January 1998 to May 2006 were investigated after obtaining the informed consent. Any patients who were treated by preoperative radiotherapy or chemotherapy were excluded. Furthermore, patients with inflammatory bowel disease or a known history of familial adenomatous polyposis were also excluded. This study was approved by the Ethics Committee of the Saitama Cancer Center.
Analysis of MSI
Primary CRCs and paired normal colorectal mucosa obtained by surgery were immediately frozen at À80°C. The genomic DNA was extracted from fresh frozen specimens using standard methods. The Bethesda five markers, BAT25, BAT26, D5S346, D2S123 and D17S250, were used to classify the MSI status of the tumors. Polymerase chain reaction (PCR) and subsequent analyses were performed as reported previously (5) . CRCs were subdivided into three groups according to the degree of MSI; MSI-H if two or more of the five markers show instability, MSI-L if only one marker shows instability and MSS if absence of MSI in all five markers. MSI-positive markers were re-examined at least twice to confirm the result. Loss of heterozygosity (LOH) was defined by at least a 30% reduction in the relative intensity of one allele in the tumor in comparison with normal levels. Analysis of KRAS, BRAF and p53 mutation The mutations in exon 1 and 2 of the KRAS gene were analyzed by denaturing gradient gel electrophoresis as described previously (36) .
The BRAF V600E mutation was examined using PCR combined with restriction enzyme digestion. DNA fragments containing exon 15 of the BRAF gene were amplified by PCR using the following oligonucleotide primers: BRAF forward primer 5#-CTGTTTTCCTTTACTTACTACACC-3# and BRAF reverse primer 5#-CTGTTCAAACTGATGGGACC-3#. PCR amplification was carried out with 100 ng of genomic DNA in a volume of 20 ll containing 0.2 lM deoxynucleoside triphosphate, 0.1 lM each of primers and 1 U Taq Gold. Thermal cycling was initiated with denaturation at 94°C for 10 min followed by 37 three-step cycles at 94°C for 30 s, 59°C for 30 s and 72°C for 45 s and followed by a final incubation for 7 min at 72°C. PCR products were digested with HpyCH4III at 37°C for 1 h and analyzed on 8% polyacrylamide gels.
The mutations in exon 5-8 of p53 gene were analyzed by denaturing gradient gel electrophoresis as described previously (37) .
Analysis of hMLH1 and MGMT promoter methylation hMLH1 and MGMT promoter methylation was analyzed in 55 of MSI-H cancer and 67 of MSI-L cancer samples. The methylation status of each gene was determined by the methods previously reported (5). The primers were hMLH1 methylation specific, 5#-AACGAATTAATAGGAAGAGGCGGATAGCG-3# and 5#-CGTCCCTCCCTAAAACGACTACTACCC-3#; hMLH1 unmethylation specific, 5#-TAAAAATGAATTAATAGGAAGAGTGGATAGTG-3# and 5#-AATCTCTTCATCCCTCCCTAAAACA-3#; MGMT methylation specific, 5#-TTTCGACGTTCGTAGGTTTTCGC-3# and 5#-GCACTCTTCCGAAAA-CGAAACG-3# and MGMT unmethylation specific, 5#-TTTGTGTTTTGA-TGTTTGTAGGTTTTTGT-3# and 5#-AACTCCACACTCTTCCAAAAACA AAACA-3#.
Statistical analysis
Differences were assessed using the chi-square or Fisher's exact test for categorical variable and unpaired Student's t-test for continuous factors. The overall survival was defined as the interval from the date of resection until the date of death from any cause, censored patients being those alive at the close of the study or lost to follow-up. Survival was measured from the date of the resection of the CRCs until death or until the censor date of 1 July 2006. The distribution of survival time was compared with the use of the log-rank test; survival distribution curves were estimated by the method of KaplanMeier. Multivariate analyses were performed with the use of the Cox proportion hazard model. The independent prognostic factors for survival were determined by a stepwise backward conditional selection in which the nonsignificant factors (P . 0.1) were successively rejected. All statistical analyses were performed using the StatView 5.5 program. P ,0.05 was considered to be statistically significant in all cases.
Results

MSI status
The Bethesda panel, BAT25, BAT26, D5S346, D2S123 and D17S250, was used to classify the MSI status of the tumors. Of the 940 CRCs, 55 (5.9%) were MSI-H, 67 (7.1%) were MSI-L and 818 (87%) were MSS (Table I) . Mononucleotide marker BAT25 and BAT26 exhibited Table I . Clinicopathological and genetic features of CRCs Well and moderately differentiated versus mucinous and poorly differentiated.
MSI-L versus MSS MSI-H versus MSS MSI-L versus MSI-H
Genetic changes in MSI-L colorectal cancer instability in 95% of MSI-H CRCs whereas in 1-3% of MSI-L CRCs. Therefore, BAT25 and BAT26 were identified to be the most specific and sensitive markers to detect MSI-H CRCs. The dinucleotide marker D2S123 exhibited instability not only in 95% of the MSI-H CRCs but also in 56.7% of MSI-L. D2S123 is the most sensitive but not specific for MSI-L ( Figure 1A ).
Clinicopathological features
The association of MSI status with the clinicopathological features in the 940 CRCs is shown in Table I . Consistent with the findings of previous studies, MSI-H cancers are observed more frequently in females, in the proximal colon and in poorly differentiated or mucinous CRCs in comparison with MSS. While some differences were observed between MSI-L and MSS cancer, with regard to the female to male ratio, the site of the tumor and the stage did not reach significance. The prognosis was assessed based on the MSI status ( Figure 1B ). Since no Dukes' A patients died during the follow-up period, these patients were excluded from the overall survival analysis. In total, 155 of the 731 Dukes' B-D patients (21.2%) died during a mean follow-up period of 30.3 ± 19 months after surgery. The prognosis of patients with MSI-H tumors was significantly better than that of patients with MSS tumors (log-rank test, P 5 0.0335). The prognosis of patient with MSI-L tumors had an intermediate tendency among the three groups ( Figure 1B) .
In a stepwise multivariate analysis, age {hazard ratio (HR) 
Mutation analysis of the KRAS and BRAF genes
A KRAS mutation was detected in 39.4% and a BRAF V600E mutation in 4.6% of the 905 CRCs that were examined. The BRAF mutation was found more frequently in MSI-H cancer (32%) in comparison with MSS (3%) and MSI-L cancers (4%; P , 0.0001, Figure 2A ). The frequency of BRAF mutation decreased accompanying the tumor progression in MSI-H cancer, whereas it increased in MSI-L and MSS cancers ( Figure 2D-F) .
The KRAS mutation analysis in CRCs demonstrated that MSI-L cancer showed higher frequency of the KRAS mutation than MSS and MSI-H cancers: MSS 39% (311/788), MSI-H 30% (16/53) and MSI-L 48% (32/67; MSI-L versus MSI-H; P 5 0.066, MSI-L versus MSS; P 5 0.244, MSI-H versus MSS; P 5 0.180; Figure 2A ). However, accompanying the progression from Dukes' A to Dukes' B, the frequency of the KRAS mutation in MSI-L cancer drastically increased from 16 to 63% ( Figure 2E , MSI-L; KRAS mutation in Dukes A versus KRAS mutation in Dukes B-D, P 5 0.045, Fisher's exact test) and was significantly higher than that in MSS or MSI-H cancers at Dukes' B-D (MSI-L versus MSS or MSI-H; P 5 0.014, P 5 0.0394, respectively; Figure 2C ). MSI-H cancer also demonstrated an increased proportion of the KRAS mutation accompanying the progression from Dukes' A to Dukes' B ( Figure 2F ), but the number of MSI-H cases was too small to find significance (MSI-H; KRAS mutation in Dukes' A versus KRAS mutation in Dukes' B-D, P 5 0.08, Fisher's exact test). The ratio of the KRAS mutation in MSI-H cancer was the same as that in MSS cancer after Dukes' B stage ( Figure 2C ).
The ratio of tumors having either the KRAS or BRAF mutation at Dukes' B-D in MSI-H and MSI-L cancers was statistically higher than that in MSS cancer [MSS (40%) versus MSI-L (66%) or MSI-H (63%)
; P 5 0.0034, P 5 0.0108, respectively; Figure 2C ].
Type of KRAS mutation
Of the 321 tumors with KRAS mutations, 196 (61%) were a G to A transition, 107 (33%) were a G to T transversion and 18 (6%) were a G to C transversion. The type of KRAS mutation was investigated in each MSI status. This revealed that 93% (14 of 15 tumors) of the KRAS mutations were a G to A transition in MSI-H cancer and there were significant differences between the types of KRAS mutations among the three MSI groups (P 5 0.0152, chi-square test). The frequency of G to A transition mutations in MSI-L cancer was lower than in MSI-H but higher than in MSS cancer ( Figure 2G ). To investigate whether the high frequency of G to A transition mutation of KRAS gene in MSI-H and MSI-L cancer is involved in the inactivation of hMLH1 or MGMT, the methylation status of the hMLH1 and MGMT promoter was analyzed. Of the 30 MSI-L tumors with KRAS mutations, 13 (43%) had MGMT promoter methylation, whereas among 35 MSI-L tumors without KRAS mutations, 10 (29%) had it (Table II) . Furthermore, 53% (10 of 19) of MSI-L tumors with G to A transition mutations in KRAS harbored MGMT promoter methylation, whereas 30% (three of 10) of MSI-L tumors with G to C or T transversion mutations in KRAS and 29% (10 of 35) of MSI-L tumors without a KRAS mutation showed MGMT promoter methylation (G to A versus G to C or T and wild-type, P 5 0.0705; Table III) .
These results suggest that G to A transition mutations in MSI-L tumors seem to correlate with MGMT promoter methylation (P 5 0.0705). On the other hand, the frequency of MGMT methylation was observed in 38% of MSI-H tumors with KRAS mutation and 56% of MSI-H tumor without KRAS mutations. This result suggests that there is an inverse correlation between KRAS mutations and MGMT methylation in MSI-H tumors (P 5 0.2026; Table II ).
The frequency of hMLH1 methylation was observed 25% of MSI-H tumors with KRAS mutations and 59% of MSI-H tumors without KRAS mutations. This result clearly shows a significant inverse correlation between KRAS mutations and hMLH1 methylation in MSI-H tumors (P 5 0.0366). The frequency of hMLH1 methylation was Table II) .
LOH of D5S346 and p53 mutation in MSI-L CRCs
Since D5S346, one of the MSI makers, locates near the APC gene, MSI analysis with the Bethesda panel can also assess the LOH of APC gene, simultaneously. LOH of the D5S346 and p53 mutation was detected in 75% (9/12) and 67% (12/18) of MSI-L CRC at Dukes' A, respectively (Table IV) . In addition, the frequency of LOH of D5S346 and p53 mutations in MSI-L at Dukes' B-D were 55 and 61%, respectively. These results indicate that LOH of APC and p53 mutations has already occurred before Dukes' A. 
Genetic changes in MSI-L colorectal cancer
Discussion
Molecular features
Although the BRAF and KRAS mutations are found more frequently in MSI-H and MSI-L CRC, respectively (31, 34, 38) , the frequency of KRAS and BRAF mutation changed between each tumor stage in this study.
The development of CRC requires a multistep process characterized by the accumulation of genetic alterations. According to the well-known genetic model for colorectal tumorigenesis proposed by Fearon and Vogelstein, KRAS mutations occur in the early to intermediate adenomas (3). However, the frequency of KRAS mutations was significantly lower (16%) at Dukes' A and higher (60%) at Dukes' B-D in MSI-L CRCs. This means that most KRAS mutations occurred at different times in MSI-L CRC, namely, during the progression from Dukes' A to Dukes' B but not in early to intermediate adenomas. It has been reported previously that the KRAS mutation is found more frequently in MSI-L CRCs (31, 32) , but according to the current detailed study, it depends on the tumor stage. Since a large number of specimens were collected in an unbiased manner for this study, the results demonstrate representative findings of CRCs in Japan.
Meanwhile LOH of D5S346, which is located near the APC gene, and the p53 mutation was observed in 75% (9/12) and 67% (12/18) of MSI-L CRC at Dukes' A, respectively. These frequencies were almost the same at Dukes' B-D in MSI-L CRC (Table IV) .
Taken together, these findings indicated that LOH of APC and p53 mutations have already occurred by the Dukes' A lake suppressor pathway but not the KRAS mutation in MSI-L CRCs.
MSI-L CRC may develop through a mild mutator pathway, which differs from the suppressor and mutator pathway and show different clinical features (31, 39) . However, some studies doubt the presence of the MSI-L group (27, 30) . In the current study, the involved genes such as LOH of APC, KRAS and p53 mutation in MSI-L CRCs are similar to those in MSS CRCs, but at least the timing and frequency of the KRAS mutation is different. This may explain why the clinicopathological features of MSI-L tumors are similar to those of MSS tumors but not completely identical.
On the other hand, considering the presence of the BRAF mutation and methylation of the hMLH1 promoter at the early stage in MSI-H CRC, these genetic changes should occur in the precursor of MSI-H CRC. This is not inconsistent with the concept of serrated pathways resulting from serrated polyps that were revealed in recent morphological and molecular studies (24) (25) (26) (40) (41) (42) .
The mechanism of the KRAS mutation was also analyzed and the results showed that a G to A transition mutation of KRAS occurs more frequently in MSI-L than MSS. Some reports demonstrated that MGMT inactivation by promoter methylation causes a G to A transition mutation of KRAS (33, 43, 44) and p53 (45) and such a mutation is frequently observed in MSI-L CRCs. We attempted to determine whether or not the inactivation of MGMT by promoter methylation is associated with the type and frequency of KRAS mutation. Our results indicated that MGMT promoter methylation seems to affect the G to A transition and frequency of the KRAS mutation in MSI-L CRC. However, most KRAS mutations in MSI-H CRC show a G to A transition, MGMT inactivation was inversely related and the BRAF mutation often observed in MSI-H CRC shows a T to A transversion. Considering these results, a different mechanism might therefore be involved in mutation between MSI-L and MSI-H CRC.
Clinical feature
As mention above, the genes associated with developing MSI-L CRC are similar to the suppressor pathway but the frequency and timing of KRAS mutations is different; thus, there may be different clinical and pathological features in MSI-L.
Comparing the stage distribution for each MSI status, the distribution of Dukes' B in MSI-H CRC is significantly larger than in MSS and MSI-L CRC (7). Gyef et al. (15) demonstrated with a logistic analysis that MSI-H CRC is less metastatic to the regional lymph nodes and distant organs than MSS CRC, even though their depth of tumor invasion is same. The same result was observed in the current study, but MSI-L CRC did not show this characteristic. This suggests that there is a mechanism restricting the progression from Dukes' B to C in MSI-H cancer. Although the precise explanation for this mechanism is still unknown, tumor-infiltrating lymphocytes, apoptosis, proliferative activity (46, 47) or a mutation of p53 (7) may lead to the 'restraining effect'.
On the other hand, the distribution of Dukes' A in MSI-L CRC is larger than MSS. Considering the KRAS mutation during the progression from Dukes' A to B in MSI-L CRC, tumor progression may be hindered until the occurrence of the KRAS mutation in MSI-L CRC.
Various studies have reported the prognosis of each MSI status. Some investigations show that the patients with MSI-H cancer demonstrate a better prognosis and the patients with MSI-L cancer have a poorer survival than patients with MSS in stage C (48, 49) . Considering the high frequency of the KRAS mutation after Dukes' B in MSI-L cancer, the worse prognosis of such patients may therefore be reasonable (50) .
Although the number of cases in the current study was not sufficient to study the prognosis at each stage, among all patients with Dukes' B to D CRCs, MSI-H patients showed significantly better survival than MSS (log-rank test, P 5 0.0335) while MSI-L patients had a slightly better prognosis than MSS. These findings may result from the fact that the proportion of Dukes' D for each MSI status is smaller, in order, MSI-H, MSI-L and MSS. (44) M, methylated; U, unmathylated; Wt, wild type. P : G to A versus G to C, T þ Wt.
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Furthermore, MSI-L tumors in the current series developed more frequently in females and in the proximal colon than MSS tumors, although no significant difference was observed.
In this study, a series of 940 patients with CRCs suggests that MSI-H, MSI-L and MSS cancer each progress through different pathways. Further study on these themes will probably attempt to clarify not only MSI cancer but also try to elucidate the true nature of CRCs itself.
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